Regimen selection in the OPTIONS trial of HIV salvage therapy: drug resistance, prior therapy, and race–ethnicity determine the degree of regimen complexity
Year: 2020
Type: article
Abstract: Regimen selection for highly treatment-experienced patients is complicated.
DOI: 10.17615/fp9j-3v97
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: green
Funders: Boehringer Ingelheim, Abbott Laboratories, Bristol-Myers Squibb, Pfizer, GlaxoSmithKline, Massachusetts General Hospital, Gilead Sciences, University of Southern California, Purdue University, Children's Hospital of Philadelphia, Harvard University, Harvard University Center for AIDS Research, National Institutes of Health, Center for AIDS Research, University of Washington, University of North Carolina at Chapel Hill, University of California, San Diego, National Institute of Mental Health, National Institute of Allergy and Infectious Diseases, National Institute of Child Health and Human Development, National Institute of Dental and Craniofacial Research
Awards: G115468880, G174905615, G1939027404, G1951574862, G2230551448, G4166928756, G473273920, G5687345013, G5937357401, G654751394, G7785852513, G7871313406, G8541996175, G9000008330, G9000075494, G9000129761, G9000130697, G9000134703, G9000225493, G9000334266, Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, Providence/Boston Center for AIDS Research (CFAR), The University of North Carolina Center for AIDS Research
OpenAlex ID: W4299335795